Skip to content
Therapy But Better – Lifestyle
Author:
Belite Bio, Inc
Belite Bio Announces Multi-Market Submission of Marketing Authorization Applications Via the Access Consortium Pathway for Tinlarebant for the Treatment of Stargardt Disease Type 1
October 14, 2026
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
October 1, 2026
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
September 28, 2026
Belite Bio submits tinlarebant NDA in Japan for Stargardt Disease
September 8, 2026
Belite Bio to Participate in Four Upcoming Investor Conferences
September 1, 2026
Belite Bio to Host Virtual Commercial Day on September 2, 2026
August 24, 2026
Belite Bio Announces Oral Presentations at Two Upcoming Medical Conferences
August 21, 2026
Belite Bio Reports Unaudited Second Quarter 2026 Financial Results and Provides a Corporate Update
August 12, 2026
Belite Bio Announces U.S. Food and Drug Administration Acceptance and Priority Review of New Drug Application for Tinlarebant for the Treatment of Stargardt Disease Type 1
August 11, 2026
Belite Bio to Host Webcast on August 13, 2026, to Discuss Second Quarter 2026 Financial Results
August 6, 2026
1
2
3
Next Page
→